A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers
NCT07103278
Benign Prostatic Hyperplasia, Genital Diseases
Seoul, South Korea
View Trial DetailsNCT Number: NCT00593593
This study has 4 phases: screening phase (visit 1), treatment phase (visit 2 - 6 mths after treatment initiation), and end of treatment phase (visit 3 - end of year 1). Only in the case a serious adverse event (SAE) arises, will there be a follow up phase (visit 4).
Looking for future studies?
Notify MeMale
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
GlaxoSmithKline
Industry
A Pharmacovigilance Study to Evaluate Safety of AVODART (Dutasteride) Administration 0,5 mg Once Daily, for 52 Weeks, in Subjects With Benign Prostate Hyperplasia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07103278
Benign Prostatic Hyperplasia, Genital Diseases
Seoul, South Korea
View Trial DetailsNCT06589154
Benign Prostatic Hyperplasia, Genital Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT07715448
Benign Prostatic Hyperplasia, Ejaculatory Dysfunction
Banī Suwayf, Beni Suef Governorate, Egypt
View Trial DetailsNCT05200065
Benign Prostatic Hyperplasia, Genital Diseases
Cairo, Cairo Governorate, Egypt
View Trial Details